DanDrit Biotech USA, Inc. — FY2014 Form 10-K Summary
Filing identity: The provided filing is for DanDrit Biotech USA, Inc., not Lunai Bioworks Inc. It reports the fiscal year ended December 31, 2014; the filing does not present a separate fourth-quarter income statement.
Business context and reporting period
DanDrit is a clinical-stage biotechnology company developing MelCancerVac (MCV), an autologous dendritic-cell vaccine focused primarily on stage IV colorectal cancer. MCV had completed early clinical studies in Denmark and Singapore and was available in Singapore under a named-patient compassionate-use program, but had not received FDA, EMA, or comparable marketing approval.
On February 12, 2014, DanDrit USA completed a share exchange acquiring approximately 100% of DanDrit Biotech A/S, its Danish operating subsidiary, in a reverse acquisition. The company had two full-time and one part-time employees and outsourced significant manufacturing, clinical, and regulatory activities.
Financial performance and liquidity
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Net sales | $0 | $32,768 | Down 100% |
| Gross loss | $(295,661) | $(76,531) | Loss increased $219,130 |
| Operating expenses | $2,133,565 | $1,662,417 | Up 28% |
| Loss from operations | $(2,429,226) | $(1,738,948) | Loss increased |
| Net loss | $(2,370,883) | $(2,147,361) | Loss increased 10.4% |
| Basic and diluted loss per share | $(0.32) | $(0.40) | Improved per share due to higher share count |
| Net cash used in operating activities | $(2,034,175) | $(2,130,628) | Use decreased $96,453 |
| Cash and cash equivalents | $3,008,831 | $18,794 | Significant increase |
| Cash held in escrow | $2,029,502 | $77,468 | Significant increase |
| Total assets | $5,239,909 | $450,467 | Up 1,063% |
| Total liabilities | $1,757,664 | $2,134,637 | Down 18% |
| Current working capital | $3,288,685 | $(1,993,145) | Improved substantially |
The company raised $7,377,089 from financing activities, primarily through common-stock offerings, including a $5.47 million initial public offering before offering costs and a $2.0 million private placement. Related-party debt was substantially reduced; current related-party notes payable were $99,951 at year-end, with no long-term debt reported.
Despite improved liquidity, the company remained pre-revenue and dependent on financing. Management estimated clinical-trial costs of approximately €313,104 for the following three months and approximately €100,000 per quarter during 2015, in addition to increasing manufacturing and enrollment costs.
Material changes versus the prior comparable period
- Revenue fell to zero after discontinuation of the Singapore compassionate-use program, while cost of goods sold increased to $295,661 because of lysate manufacturing technology-transfer costs.
- General and administrative expense increased 33% to $1,644,918, primarily because of audit, public-company, legal, salary, and related costs.
- Consulting expense increased 21% to $469,666, reflecting share-exchange valuation, S-1 registration, and VIVA Phase III preparation.
- Interest expense declined sharply to $84,550 from $652,703, but the net loss still increased because operating expenses and the gross loss rose.
- The February 2014 share exchange and 2014 stock offerings increased shares outstanding from 6,000,000 at December 31, 2013 to 9,533,290 at December 31, 2014.
- Cash provided by financing activities increased to $6.67 million from $2.47 million, while investing cash use increased primarily because $1.95 million was placed in escrow.
Guidance, outlook, commentary, risks, and unusual items
- Management planned a randomized, adaptive Phase III VIVA trial in Italy for 174 stage IV colorectal cancer patients rendered disease-free after surgery and chemotherapy. The proposed primary endpoints were progression-free survival at 18 months and overall survival, with an expected duration of approximately three years.
- The company expected to operate more than 30 Italian clinical sites and sought regulatory engagement with Italian, European, U.S., and potentially Chinese authorities. The filing states that the FDA had not reviewed MCV and that early clinical results may not predict later-stage success.
- Management expected future commercial value to arise through pharmaceutical acquisition, licensing, milestone payments, royalties, or partnerships, but no such commercial outcome was assured.
- Management stated that existing resources were expected to support planned operations through December 31, 2018, but also disclosed no committed external funding source and the need for additional capital if expenditures exceeded expectations.
- Major risks include continued losses, inability to raise capital, clinical-trial failure or delays, regulatory rejection, patient-enrollment challenges, reliance on contract manufacturers and CROs, competition, product liability, intellectual-property challenges, foreign-currency exposure, and dependence on collaboration partners.
- The company reported a material weakness in internal control over financial reporting arising from limited personnel, inadequate segregation of duties, and limited supervisory review. Disclosure controls were nevertheless assessed as effective at a reasonable-assurance level.
- Subsequent events included January and March 2015 collaboration agreements supporting the VIVA trial and a March 2015 transition of the Danish subsidiary’s CFO.
- The filing contains related-party transactions, including shareholder loans, related-party leases, legal services from a firm associated with the chairman, and approximately $212,438 payable to a related law firm at year-end.
Investor verification checklist
- Confirm the issuer identity: the source filing names DanDrit Biotech USA, Inc., whereas the request metadata names Lunai Bioworks Inc.
- Verify the audited financial statements, particularly the apparent inconsistency between the $3.01 million cash balance and $2.03 million held in escrow.
- Assess whether the planned VIVA Phase III trial was actually initiated, funded, enrolled, and accepted by applicable regulators.
- Review subsequent financing, dilution, related-party transactions, and the status of the $2.0 million shareholder support commitment that expired in March 2015.
- Evaluate the material internal-control weakness and whether remediation was completed.
- Independently validate clinical efficacy and safety claims because MCV had not received regulatory approval and the cited studies were largely small, single-arm, or early-stage trials.
- Review cash burn, clinical-trial commitments, patent status, manufacturing arrangements, and the company’s ability to continue operations without additional financing.